JP7177773B2 - β－セクレターゼ阻害剤としてのオキサジン誘導体および使用方法 - Google Patents

β－セクレターゼ阻害剤としてのオキサジン誘導体および使用方法 Download PDF

Info

Publication number
JP7177773B2
JP7177773B2 JP2019531733A JP2019531733A JP7177773B2 JP 7177773 B2 JP7177773 B2 JP 7177773B2 JP 2019531733 A JP2019531733 A JP 2019531733A JP 2019531733 A JP2019531733 A JP 2019531733A JP 7177773 B2 JP7177773 B2 JP 7177773B2
Authority
JP
Japan
Prior art keywords
compound
tautomer
dihydro
pharmaceutically acceptable
fluorovinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019531733A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020503293A5 (enExample
JP2020503293A (ja
Inventor
アレン，ジェニファー・アール
ブルボー，マシュー・ピー
チェン，ニン
フローン，マイケル・ジェイ
ハリントン，ポール・イー
リウ，チンイエン
リーブス，コウリー
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2020503293A publication Critical patent/JP2020503293A/ja
Publication of JP2020503293A5 publication Critical patent/JP2020503293A5/ja
Application granted granted Critical
Publication of JP7177773B2 publication Critical patent/JP7177773B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • C07D265/08—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychiatry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2019531733A 2016-12-15 2017-12-13 β－セクレターゼ阻害剤としてのオキサジン誘導体および使用方法 Active JP7177773B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662434711P 2016-12-15 2016-12-15
US62/434,711 2016-12-15
US201762570425P 2017-10-10 2017-10-10
US62/570,425 2017-10-10
PCT/US2017/066177 WO2018112081A1 (en) 2016-12-15 2017-12-13 Oxazine derivatives as beta-secretase inhibitors and methods of use

Publications (3)

Publication Number Publication Date
JP2020503293A JP2020503293A (ja) 2020-01-30
JP2020503293A5 JP2020503293A5 (enExample) 2021-01-28
JP7177773B2 true JP7177773B2 (ja) 2022-11-24

Family

ID=60888744

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019531733A Active JP7177773B2 (ja) 2016-12-15 2017-12-13 β－セクレターゼ阻害剤としてのオキサジン誘導体および使用方法

Country Status (8)

Country Link
US (1) US10947223B2 (enExample)
EP (1) EP3555080B1 (enExample)
JP (1) JP7177773B2 (enExample)
AU (1) AU2017376441B2 (enExample)
CA (1) CA3047286A1 (enExample)
MA (1) MA52722A (enExample)
MX (1) MX388696B (enExample)
WO (1) WO2018112081A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA110467C2 (uk) † 2009-12-11 2016-01-12 Шионогі Енд Ко., Лтд. Похідні оксазину
US10947223B2 (en) 2016-12-15 2021-03-16 Amgen Inc. Substituted oxazines as beta-secretase inhibitors
CA3047287A1 (en) 2016-12-15 2018-06-21 Amgen Inc. Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use
JP7148518B2 (ja) 2016-12-15 2022-10-05 アムジエン・インコーポレーテツド β－セクレターゼ阻害剤としての二環式チアジンおよびオキサジン誘導体ならびに使用方法
MX387729B (es) 2016-12-15 2025-03-18 Amgen Inc Derivados de dióxido de 1,4-tiazina y dióxido 1,2,4-tiadiazina como inhibidores de beta-secretasa y métodos de uso.
WO2018112083A1 (en) 2016-12-15 2018-06-21 Amgen Inc. Thiazine derivatives as beta-secretase inhibitors and methods of use
CA3098430A1 (en) 2018-04-27 2019-10-31 Shionogi & Co., Ltd. Tetrahydropyranooxazine derivatives having selective bace1 inhibitory activity

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014505688A (ja) 2011-01-12 2014-03-06 ノバルティス アーゲー オキサジン誘導体および神経障害の処置におけるその使用
JP2014524463A (ja) 2011-08-25 2014-09-22 ノバルティス アーゲー ２−アミノ−４−（ピリジン−２−イル）−５，６−ジヒドロ−４ｈ−１，３−オキサジン誘導体およびｂａｃｅ−１および／またはｂａｃｅ−２阻害剤としてのそれらの使用
JP2015514073A (ja) 2012-03-20 2015-05-18 エラン ファーマシューティカルズ， リミテッド・ライアビリティ・カンパニー スピロ環式ジヒドロ−チアジンおよびジヒドロ−オキサジンｂａｃｅ阻害剤、ならびにその組成物および使用
JP2016510758A (ja) 2013-03-08 2016-04-11 アムジエン・インコーポレーテツド β−セクレターゼ阻害剤としての過フッ素化シクロプロピル縮合１，３−オキサジン−２−アミン化合物、及び使用方法
JP7148518B2 (ja) 2016-12-15 2022-10-05 アムジエン・インコーポレーテツド β－セクレターゼ阻害剤としての二環式チアジンおよびオキサジン誘導体ならびに使用方法
JP7149271B2 (ja) 2016-12-15 2022-10-06 アムジエン・インコーポレーテツド β－セクレターゼ阻害剤としての１，４－チアジンジオキシドおよび１，２，４－チアジアジンジオキシド誘導体ならびに使用方法
JP7149272B2 (ja) 2016-12-15 2022-10-06 アムジエン・インコーポレーテツド β－セクレターゼ阻害剤としてのチアジン誘導体および使用方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441870A (en) 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
SI9300303A (en) 1993-06-08 1994-12-31 Krka Tovarna Zdravil Process for isolation of hypolipemic effective substance
AU6383396A (en) 1995-06-07 1996-12-30 Athena Neurosciences, Inc. Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition
KR100691601B1 (ko) 1998-09-24 2007-03-09 파마시아 앤드 업존 캄파니 엘엘씨 알츠하이머병 세크레타제
AU2006307314C1 (en) * 2005-10-25 2011-08-25 Shionogi & Co., Ltd. Aminodihydrothiazine derivative
JP5383483B2 (ja) 2007-04-24 2014-01-08 塩野義製薬株式会社 アルツハイマー症治療用医薬組成物
ES2476605T3 (es) 2007-04-24 2014-07-15 Shionogi & Co., Ltd. Derivados de aminohidrotiazina sustituidos con grupos cíclicos
ES2548774T3 (es) 2008-01-18 2015-10-20 Eisai R&D Management Co., Ltd. Derivado de aminodihidrotiazina condensado
TWI431004B (zh) 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
AU2009258496B8 (en) 2008-06-13 2014-06-26 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
WO2010013302A1 (ja) 2008-07-28 2010-02-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 スピロアミノジヒドロチアジン誘導体
WO2010013794A1 (en) 2008-07-28 2010-02-04 Eisai R&D Management Co., Ltd. Spiroaminodihydrothiazine derivatives
KR20110076965A (ko) 2008-09-30 2011-07-06 에자이 알앤드디 매니지먼트 가부시키가이샤 신규한 축합 아미노 디하이드로티아진 유도체
AR077277A1 (es) 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
US20110065695A1 (en) 2009-09-11 2011-03-17 Jeremy Beauchamp Use of aminodihydrothiazines for the treatment or prevention of diabetes
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
US20120238557A1 (en) 2009-11-13 2012-09-20 Shionogi & Co., Ltd. Aminothiazine or aminooxazine derivative having amino linker
EP2514747A4 (en) 2009-12-09 2013-05-08 Shionogi & Co SUBSTITUTED AMINOTHIAZINE DERIVATIVE
UA103272C2 (uk) 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
UA110467C2 (uk) * 2009-12-11 2016-01-12 Шионогі Енд Ко., Лтд. Похідні оксазину
PT2663561E (pt) 2011-01-13 2016-06-07 Novartis Ag Derivados heterocíclicos novos e sua utilização no tratamento de distúrbios neurológicos
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
EP2694489B1 (en) 2011-04-07 2017-09-06 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
AU2012243329B2 (en) 2011-04-13 2015-09-17 Merck Sharp & Dohme Corp. 5-substituted iminothiazines and their mono-and dioxides as BACE inhibitors,compositions,and their use
WO2012147762A1 (ja) 2011-04-26 2012-11-01 塩野義製薬株式会社 ピリジン誘導体およびそれを含有するｂａｃｅ１阻害剤
EP2517898A1 (de) 2011-04-29 2012-10-31 Lanxess Deutschland GmbH Kieselsäurehaltige Kautschukmischungen mit schwefelhaltigen Additiven
US8785436B2 (en) 2011-05-16 2014-07-22 Hoffmann-La Roche Inc. 1,3-oxazines as BACE 1 and/or BACE2 inhibitors
US8604024B2 (en) 2011-05-24 2013-12-10 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
WO2012162334A1 (en) 2011-05-24 2012-11-29 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
US8927535B2 (en) 2011-07-06 2015-01-06 Hoffman-La Roche Inc. Cyclopropyl-fused-1,3-thiazepines as BACE1 and/or BACE2 inhibitors
KR20140054295A (ko) 2011-08-22 2014-05-08 머크 샤프 앤드 돔 코포레이션 Bace 억제제로서의 2-스피로-치환된 이미노티아진 및 그의 모노- 및 디옥시드, 조성물 및 그의 용도
WO2013030713A1 (en) 2011-08-31 2013-03-07 Pfizer Inc. Hexahydropyrano [3,4-d][1,3] thiazin-2-amine compounds
CA2872154C (en) 2012-05-04 2016-08-23 Pfizer Inc. Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin-2-amine compounds as inhibitors of app, bace1 and bace2
WO2013182638A1 (en) 2012-06-08 2013-12-12 H. Lundbeck A/S 2 -aminothiazinylheteroaryls as bace1 inhibitors for the treatment alzheimer's disease
GB201212871D0 (en) 2012-07-20 2012-09-05 Eisai Ltd Novel compounds
WO2014045162A1 (en) 2012-09-20 2014-03-27 Pfizer Inc. ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-ANIME COMPOUNDS
US9416129B2 (en) 2012-10-17 2016-08-16 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as BACE inhibitors, compositions and their use
WO2014062549A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2912035A4 (en) 2012-10-24 2016-06-15 Shionogi & Co DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY
LT2912041T (lt) 2012-10-26 2017-03-10 Eli Lilly And Company Tetrahidropiroltiazino dariniai kaip bace slopikliai
US9447085B2 (en) 2012-12-14 2016-09-20 Merck Sharp & Dohme Corp. Iminothiadiazine dioxides containing a thioamide, amidine, or amide oxime group as BACE inhibitors, compositions, and their use
US9475784B2 (en) 2012-12-19 2016-10-25 Bristol-Myers Squibb Company 4,6-diarylaminothiazines as BACE1 inhibitors and their use for the reduction of beta-amyloid production
JP6162820B2 (ja) 2012-12-19 2017-07-12 ファイザー・インク 炭素環式および複素環式置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
AU2013363151A1 (en) 2012-12-20 2015-06-04 Merck Sharp & Dohme Corp. C5, C6 oxacyclic-fused iminothiazine dioxide compounds as BACE inhibitors
EP2934534B1 (en) 2012-12-21 2017-12-13 Merck Sharp & Dohme Corp. C5-spiro iminothiadiazine dioxides as bace inhibitors
TWI593692B (zh) 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物
JP6576433B2 (ja) 2014-08-08 2019-09-18 アムジエン・インコーポレーテツド β−セクレターゼ阻害剤としてのシクロプロピル縮合チアジン−２−アミン化合物及び使用方法
EP3250035B1 (en) 2015-04-21 2023-01-25 Allgenesis Biotherapeutics Inc. Compounds and their use as bace1 inhibitors
WO2017024180A1 (en) 2015-08-06 2017-02-09 Amgen Inc. Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
US10947223B2 (en) 2016-12-15 2021-03-16 Amgen Inc. Substituted oxazines as beta-secretase inhibitors
CA3047287A1 (en) 2016-12-15 2018-06-21 Amgen Inc. Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014505688A (ja) 2011-01-12 2014-03-06 ノバルティス アーゲー オキサジン誘導体および神経障害の処置におけるその使用
JP2014524463A (ja) 2011-08-25 2014-09-22 ノバルティス アーゲー ２−アミノ−４−（ピリジン−２−イル）−５，６−ジヒドロ−４ｈ−１，３−オキサジン誘導体およびｂａｃｅ−１および／またはｂａｃｅ−２阻害剤としてのそれらの使用
JP2015514073A (ja) 2012-03-20 2015-05-18 エラン ファーマシューティカルズ， リミテッド・ライアビリティ・カンパニー スピロ環式ジヒドロ−チアジンおよびジヒドロ−オキサジンｂａｃｅ阻害剤、ならびにその組成物および使用
JP2016510758A (ja) 2013-03-08 2016-04-11 アムジエン・インコーポレーテツド β−セクレターゼ阻害剤としての過フッ素化シクロプロピル縮合１，３−オキサジン−２−アミン化合物、及び使用方法
JP7148518B2 (ja) 2016-12-15 2022-10-05 アムジエン・インコーポレーテツド β－セクレターゼ阻害剤としての二環式チアジンおよびオキサジン誘導体ならびに使用方法
JP7149271B2 (ja) 2016-12-15 2022-10-06 アムジエン・インコーポレーテツド β－セクレターゼ阻害剤としての１，４－チアジンジオキシドおよび１，２，４－チアジアジンジオキシド誘導体ならびに使用方法
JP7149272B2 (ja) 2016-12-15 2022-10-06 アムジエン・インコーポレーテツド β－セクレターゼ阻害剤としてのチアジン誘導体および使用方法

Also Published As

Publication number Publication date
MA52722A (fr) 2021-04-14
MX388696B (es) 2025-03-20
AU2017376441A1 (en) 2019-07-04
WO2018112081A1 (en) 2018-06-21
EP3555080B1 (en) 2023-09-20
US20200207747A1 (en) 2020-07-02
MX2019007101A (es) 2019-12-16
CA3047286A1 (en) 2018-06-21
US10947223B2 (en) 2021-03-16
EP3555080A1 (en) 2019-10-23
JP2020503293A (ja) 2020-01-30
AU2017376441B2 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
JP7177773B2 (ja) β－セクレターゼ阻害剤としてのオキサジン誘導体および使用方法
JP7149271B2 (ja) β－セクレターゼ阻害剤としての１，４－チアジンジオキシドおよび１，２，４－チアジアジンジオキシド誘導体ならびに使用方法
JP7148518B2 (ja) β－セクレターゼ阻害剤としての二環式チアジンおよびオキサジン誘導体ならびに使用方法
JP2016510758A (ja) β−セクレターゼ阻害剤としての過フッ素化シクロプロピル縮合１，３−オキサジン−２−アミン化合物、及び使用方法
JP7149272B2 (ja) β－セクレターゼ阻害剤としてのチアジン誘導体および使用方法
JP7159161B2 (ja) β－セクレターゼ阻害剤としてのシクロプロピル縮合チアジン誘導体および使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210824

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220708

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220708

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220726

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220902

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220906

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221101

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221111

R150 Certificate of patent or registration of utility model

Ref document number: 7177773

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150